Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 685 matching trials from the live ClinicalTrials.gov search.
Conditions
Crohn Disease
Interventions
Tele-CBT
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers

OTIS Vedolizumab Pregnancy Exposure Registry

NCT02678052
Conditions
Colitis, Ulcerative, Crohn's Disease
Interventions
Vedolizumab, Other Biological Agent
Drug · Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 44 Years · Female only
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
San Diego, California
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Zasocitinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Glen Burnie, Maryland • Tyler, Texas
Conditions
Crohn's Disease, Ulcerative Colitis (UC), Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)
Interventions
Empowered Relief, Living Better with Chronic Pain
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Crohn's Disease
Interventions
Ontamalimab, Placebo
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
48
States / cities
Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 41 more
Conditions
Crohn's Disease
Interventions
vedolizumab, Placebo
Drug · Other
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
40
States / cities
Lafayette, Colorado • Hamden, Connecticut • Gainesville, Florida + 36 more
Conditions
Crohn Disease
Interventions
Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
77
States / cities
Dothan, Alabama • Chandler, Arizona • Scottsdale, Arizona + 65 more
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
27
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 22 more
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility of Insomnia Tracking and Treatment in IBD

NCT04132024
Conditions
Inflammatory Bowel Diseases, Insomnia
Interventions
Cognitive Behavioral Therapy for Insomnia (CBT-I)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Remote monitoring
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more
Conditions
Crohn's Disease
Interventions
GSK1605786A
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Little Rock, Arizona • Tucson, Arizona • La Jolla, California + 35 more
Conditions
Crohn's Disease
Interventions
Semapimod
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Chicago, Illinois • Great Neck, New York • New York, New York
Conditions
Crohn Disease
Interventions
Sargramostim (Leukine), Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • New Orleans, Louisiana + 4 more
Conditions
Crohn's Disease
Interventions
Biopsies, stool and blood collection
Other
Lead sponsor
Enterome
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Crohn's Disease
Interventions
Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
64
States / cities
Dothan, Alabama • Mobile, Alabama • Coronado, California + 56 more
Conditions
Crohn's Disease
Interventions
Growth Hormone, Nutraceutical Combination, Exclusion Diet, Placebo Growth Hormone
Drug · Dietary Supplement · Other
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Pediatric Crohn's Disease
Interventions
Enhanced Pre-Consent Discussion, Standard Pre-consent Discussion
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Terminated Phase 4 Interventional Results available

Cimzia Versus Mesalamine for Crohn's Recurrence

NCT01696942
Conditions
Crohn's Disease
Interventions
Cimzia, Mesalamine
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Inflammatory Bowel Diseases, Crohn's Disease
Interventions
Placebo, MORF-057
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 85 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
25
States / cities
Lancaster, California • San Diego, California • Colorado Springs, Colorado + 21 more
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Digital self-management program, Standard Care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Crohns Disease, Fistula, Abscess
Interventions
Exam under anesthesia (EUA)
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania • Nashville, Tennessee
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability

NCT03962998
Conditions
Crohn Disease
Interventions
Lactulose/Rhamnose solution, MB-102
Drug
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Crohn's Disease
Interventions
autologous CD34-selected peripheral blood stem cells transplant, Alemtuzumab, ATG, Melphalan, Thiotepa, Rituximab, Cyclophosphamide, G-CSF, Mesna
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
10 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Conditions
Crohn's Disease
Interventions
SAR442970, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Tucson, Arizona • Escondido, California • Lancaster, California + 16 more